Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07579741RecruitingPhase 1/Phase 2
Testing JL18008 for HIV Patients Not Recovering Immune Cells
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
Beijing, Beijing MunicipalityAges 18–65 - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT06640192RecruitingPhase 2
High-dose HIV drugs to clear hidden virus
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Madrid, MadridAges 18–60 - NCT05187429RecruitingPhase 1/Phase 2
Low-dose nivolumab for adults with HIV on stable therapy
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Melbourne, VictoriaAges 18–65 - NCT07433387RecruitingPhase 1/Phase 2
Study of a new HIV drug for people not on treatment
This trial tests a new injectable treatment called LP-98 for people with HIV who have never taken HIV medications before. It aims to see if the drug is safe and can help lower the virus in your body.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05808166RecruitingPhase 2
Hepatitis E vaccine test in healthy pregnant women
This Phase 2 study tests the safety of Hecolin® (a hepatitis E vaccine) and how well it helps the body build protection in healthy pregnant women. You might be invited if you’re pregnant during specific weeks and healthy enough for vaccination and follow-up blood tests.
Karachi, SindhAges 16–45 - NCT07342868RecruitingPhase 1
Single dose study for liver health
This trial tests a single dose of an experimental drug called pevifoscorvir in people with moderate liver problems and in healthy people. It aims to see how the body processes the drug and if it is safe.
Orlando, FloridaAges 18–75 - NCT06904820Recruiting
Hepatitis and HIV screening for drug users
This trial tests a convenient way to screen people who use drugs or are in vulnerable situations for hepatitis B, C, and HIV using rapid tests and a liver scanner. The goal is to see if offering these tests in community settings (like shelters or mobile clinics) is acceptable and works well.
LimogesAges 18 years+ - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT07704164RecruitingPhase 2
Colchicine to lower heart artery swelling in HIV
This trial tests if colchicine, a medicine for inflammation, can reduce swelling in the heart arteries of people with HIV. It may help lower the risk of heart problems in those already on a statin or similar medication.
BarcelonaAges 50 years+ - NCT03684655RecruitingPhase 2
PET-MR scan study of immune activity in people with HIV
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
San Francisco, CaliforniaAges 18 years+ - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT04653610Recruiting
Study immune signals in untreated HIV using extra samples
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
Ghent, Oost-VlaanderenAges 18–65 - NCT04883255RecruitingEarly Phase 1
Study cannabis effects on brain function in adults with HIV
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
San Diego, CaliforniaAges 18–65 - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT05392387Recruiting
Treatment and outcomes study for long-term hepatitis B
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Changsha, HunanAges 18–79 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05947890RecruitingPhase 2
Testing an immune-boosting TB vaccine in people with or without HIV
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Johannesburg, GautengAges 12–55 - NCT05988879Recruiting
Functional cure for hepatitis B in HIV/HBV co-infection
This trial tests whether people with both HIV and hepatitis B can achieve a functional cure for hepatitis B. It aims to see if current treatment can be stopped safely after the hepatitis B virus is no longer active.
Guangzhou, GuangdongAges 18–65
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 794 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.